Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.

Building on that momentum, we expect to again deliver sequentially higher revenue and non-GAAP gross margin in the current first quarter. As you've consistently heard from us, we're focused on and ...